Janus kinase inhibitors: between prescription authorization and reimbursability

• Egile Nagusiak: F.R. Spinelli (Egilea), F. Conti (Egilea), R. Caporali (Egilea), F. Iannone (Egilea), F. Cacciapaglia (Egilea), on behalf of the Steering Committee of the Italian Society of Rheumatology (Egilea)
• Formatua: Liburua
• Argitaratua: PAGEPress Publications, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.